RU2007135030A - Композиции и способы классификации биологических образцов - Google Patents

Композиции и способы классификации биологических образцов Download PDF

Info

Publication number
RU2007135030A
RU2007135030A RU2007135030/15A RU2007135030A RU2007135030A RU 2007135030 A RU2007135030 A RU 2007135030A RU 2007135030/15 A RU2007135030/15 A RU 2007135030/15A RU 2007135030 A RU2007135030 A RU 2007135030A RU 2007135030 A RU2007135030 A RU 2007135030A
Authority
RU
Russia
Prior art keywords
epitopes
informative
informative epitopes
nisch
presented
Prior art date
Application number
RU2007135030/15A
Other languages
English (en)
Russian (ru)
Inventor
Тумас НОЙМАН (US)
Тумас НОЙМАН
Михис ПОУЛД (US)
Михис ПОУЛД
Original Assignee
Симайнз, Инк. (Us)
Симайнз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Симайнз, Инк. (Us), Симайнз, Инк. filed Critical Симайнз, Инк. (Us)
Publication of RU2007135030A publication Critical patent/RU2007135030A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2007135030/15A 2005-02-24 2006-02-24 Композиции и способы классификации биологических образцов RU2007135030A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65685905P 2005-02-24 2005-02-24
US60/656,859 2005-02-24

Publications (1)

Publication Number Publication Date
RU2007135030A true RU2007135030A (ru) 2009-03-27

Family

ID=36928007

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007135030/15A RU2007135030A (ru) 2005-02-24 2006-02-24 Композиции и способы классификации биологических образцов

Country Status (11)

Country Link
US (1) US20090075832A1 (enExample)
EP (1) EP1859266A4 (enExample)
JP (1) JP2008532014A (enExample)
KR (1) KR20080003321A (enExample)
CN (1) CN101160524A (enExample)
AU (1) AU2006216683A1 (enExample)
CA (1) CA2598889A1 (enExample)
IL (1) IL185458A0 (enExample)
MX (1) MX2007010349A (enExample)
RU (1) RU2007135030A (enExample)
WO (1) WO2006091734A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322009A1 (en) 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
ES2444695T3 (es) * 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2201024A1 (en) * 2007-08-28 2010-06-30 Ramot At Tel Aviv University Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site
TWI466680B (zh) * 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
KR20110084280A (ko) 2008-11-03 2011-07-21 알레시아 바이오쎄라퓨틱스 인코포레이티드 종양 항원의 생물 활성을 특이적으로 차단하는 항체
GB0823366D0 (en) * 2008-12-22 2009-01-28 Uni I Oslo Synthesis
KR101067815B1 (ko) * 2009-02-05 2011-09-27 서울대학교산학협력단 제1형 당뇨병의 신규한 진단 마커
CN105911275B (zh) 2009-08-14 2018-06-29 加利福尼亚大学董事会 诊断自闭症的试剂盒
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
EP2691421B1 (en) 2011-03-31 2016-11-09 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
EP2745115B1 (de) * 2011-08-19 2016-05-18 Protagen AG Neues verfahren zur diagnostik von hochaffinen bindern und markersequenzen
WO2013031757A1 (ja) * 2011-08-29 2013-03-07 東レ株式会社 膵癌、乳癌、肺癌又は前立腺癌の検出用マーカー及び検査方法
WO2013104050A2 (en) 2012-01-09 2013-07-18 Alethia Biotherapeutics Inc. Method for treating breast cancer
US20130183242A1 (en) * 2012-01-18 2013-07-18 University Of Connecticut Methods for identifying tumor-specific polypeptides
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015172843A1 (en) * 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2015179469A2 (en) * 2014-05-20 2015-11-26 Kiromic, Llc Methods and compositions for treating malignancies with dendritic cells
US10526397B2 (en) 2015-01-21 2020-01-07 Inhibrx, Inc. Non-immunogenic single domain antibodies
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
EP4300101A3 (en) 2015-06-26 2024-03-20 The Regents Of The University Of California Antigenic peptides and uses thereof for diagnosing and treating autism
IL292037A (en) 2015-07-16 2022-06-01 Inhibrx Inc Multivalent and multispecific dr5-binding fusion proteins and uses thereof
HK1258386A1 (zh) * 2015-10-05 2019-11-08 Immatics Biotechnologies Gmbh 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物
EP3193173A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Serological autoantibodies as biomarker for colorectal cancer
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CR20210128A (es) * 2017-01-27 2021-04-26 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388)
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr及其相关组合物
EP3756680A1 (en) * 2019-06-26 2020-12-30 Universitat de Lleida Intermediate filament-derived peptides and their uses
EP3999525A4 (en) * 2019-07-15 2023-08-09 Geisinger Health System COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST CANCER WITH A NOVEL CAPER ALPHA MLL1 COMPLEX
CN110922492B (zh) * 2019-12-18 2022-02-15 重庆医科大学 融合肽、ctp介导的诱导cml细胞免疫应答的dc疫苗及其制备方法
CN111337678B (zh) * 2020-02-21 2023-06-06 杭州凯保罗生物科技有限公司 与肿瘤免疫治疗效果相关的生物标志物及其应用
CN116773798A (zh) * 2023-06-16 2023-09-19 北京三品医疗科技有限公司 多肽的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
EP1337667A2 (en) * 2000-11-16 2003-08-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
WO2002073209A2 (de) * 2001-03-10 2002-09-19 Affina Immuntechnik Gmbh Verfahren zur identifikation von immunreaktiven epitopen auf proteinen
WO2002084249A2 (en) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
WO2003042357A2 (en) * 2001-09-28 2003-05-22 Incyte Genomics, Inc. Enzymes
EP1578970A1 (de) * 2002-12-23 2005-09-28 Hans-Jürgen Thiesen Human-autoantigene und deren verwendung
EP1583504A4 (en) * 2002-12-26 2008-03-05 Cemines Llc METHOD AND COMPOSITIONS FOR DIAGNOSIS, FORECAST AND TREATMENT OF CANCER

Also Published As

Publication number Publication date
US20090075832A1 (en) 2009-03-19
EP1859266A4 (en) 2010-07-28
AU2006216683A1 (en) 2006-08-31
CN101160524A (zh) 2008-04-09
WO2006091734A9 (en) 2006-10-19
MX2007010349A (es) 2008-04-09
EP1859266A2 (en) 2007-11-28
WO2006091734A3 (en) 2007-02-08
CA2598889A1 (en) 2006-08-31
IL185458A0 (en) 2008-01-06
KR20080003321A (ko) 2008-01-07
WO2006091734A2 (en) 2006-08-31
JP2008532014A (ja) 2008-08-14

Similar Documents

Publication Publication Date Title
RU2007135030A (ru) Композиции и способы классификации биологических образцов
JP2008532014A5 (enExample)
Ratto et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance
Yanagawa et al. Tumor spread through air spaces is a useful predictor of recurrence and prognosis in stage I lung squamous cell carcinoma, but not in stage II and III
Norkowski et al. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology
Wasco et al. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases
Natkunam et al. Immunoblot analysis of CD34 expression in histologically diverse neoplasms
Schneider et al. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging
Minsky et al. Potentially curative surgery of colon cancer: the influence of blood vessel invasion.
Carvalho et al. Pleomorphic sarcomas: the state of the art
AR046832A1 (es) Ensayos de rastreo y metodos de tratamiento de tumores
Zuckerman et al. Pediatric melanoma: confirming the diagnosis with sentinel node biopsy
NO20072296L (no) Fremgangsmater og systemer for prognose og behandling av faste tumorer
DE602004015626D1 (de) Bei brustkrebs
Kwon et al. Histologic characteristics of thymic adenocarcinomas: clinicopathologic study of a nine-case series and a review of the literature
Schroeter et al. Deep time paleoproteomics: looking forward
Holck et al. False-negative frozen section of sentinel lymph node biopsy for breast cancer
Benayahu et al. Revisiting the type of Cespitularia stolonifera Gohar, 1938 leads to the description of a new genus and a species of the family Xeniidae (Octocorallia, Alcyonacea)
RU2005106841A (ru) Эпитопы т-клеток в эритропоэтине
Wick Metastases to bones
WO2004113574A3 (en) Methods for disease screening
Ichinose et al. DNA ploidy patterns of tumors diagnosed as metachronous or recurrent lung cancer
Wick Prognostic factors for thymic epithelial neoplasms, with emphasis on tumor staging
Lino-Silva et al. Lymph node retrieval in radical gastrectomy: the pathologist alone or the surgeon-pathologist team?
Oven Ustaalioglu et al. Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100628